Vertex is the global leader in cystic fibrosis (CF) drugs, and the company's products have both revolutionized the treatment ...

One fund just doubled down on a beaten-down tax-tech leader—here’s what they may be seeing that the market isn’t.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

Shares of Vertex Pharmaceuticals Inc. rose 6.92% to $463.13 Wednesday, on what proved to be an all-around positive trading ...

If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite ...

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after the ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...